Lista de obras - Thomas John - Dominio Público Uruguay

"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic

artículo científico publicado en 2015

A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma

artículo científico publicado en 2014

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

artículo científico publicado en 2017

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca

artículo científico publicado en 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

artículo científico publicado en 2017

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer

scientific article published on 24 October 2019

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer

artículo científico publicado en 2017

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

artículo científico publicado en 2019

Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer

scientific article published on 01 October 2011

Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?

artículo científico publicado en 2018

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

artículo científico publicado en 2009

Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer

article

Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.

artículo científico publicado en 2015

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.

artículo científico publicado en 2015

Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer

artículo científico

Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.

artículo científico publicado en 2013

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

artículo científico publicado en 2013

Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing

artículo científico publicado en 2016

Current and Evolving Methods to Visualize Biological Data in Cancer Research

artículo científico publicado en 2016

DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?

artículo científico publicado en 2019

De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer.

artículo científico publicado en 2017

Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.

artículo científico publicado en 2014

Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.

artículo científico publicado en 2016

Do randomized acupuncture studies in patients with cancer need a sham acupuncture control arm?

artículo científico publicado en 2013

ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer

scientific article published on 01 June 2008

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

artículo científico publicado en 2018

Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials

artículo científico publicado en 2019

Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma

scientific article published on 18 April 2019

Immunotherapy for malignant mesothelioma: Reality check

artículo científico publicado en 2016

Impact of universal immunohistochemistry on Lynch syndrome diagnosis in an Australian colorectal cancer cohort

artículo científico publicado en 2019

In Reply to Leone.

artículo científico publicado en 2018

Is Mesothelioma in China Rare or Misdiagnosed?

artículo científico publicado en 2017

LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC

artículo científico publicado en 2018

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

artículo científico publicado en 2016

Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

artículo científico publicado en 2012

Lung cancer in 2016: immunotherapy comes of age

artículo científico publicado en 2016

Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

artículo científico publicado en 2014

Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort

article

Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma

artículo científico publicado en 2018

Molecular predictive and prognostic markers in non-small-cell lung cancer.

artículo científico publicado en 2009

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

artículo científico publicado en 2017

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2017

Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer

artículo científico publicado en 2017

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

scientific article published on August 2009

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

artículo científico publicado en 2016

Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report

artículo científico publicado en 2012

Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.

artículo científico publicado en 2016

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

artículo científico publicado en 2018

Personalized chemosensitivity assays for mesothelioma- is it worth the effort?

artículo científico publicado en 2018

Pharmacogenetic and Germline Prognostic Markers of Lung Cancer

article

Predicting clinical outcome through molecular profiling in stage III melanoma

artículo científico publicado en 2008

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

artículo científico publicado en 2014

Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

artículo científico publicado en 2010

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

artículo científico publicado en 2016

Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors.

artículo científico

Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).

artículo científico publicado en 2016

Should we screen for lung cancer in Australia?

artículo científico publicado en 2013

Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease

scientific article published on 01 May 2019

Standard of care in immunotherapy trials: Challenges and considerations.

artículo científico publicado en 2017

Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate

artículo científico publicado en 2020

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

artículo científico publicado en 2016

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.

artículo científico publicado en 2016

The ADAM Trial: Visiting the Road Less Traveled

artículo científico publicado en 2017

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

artículo científico publicado en 2017

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

artículo científico publicado en 2010

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

artículo científico publicado en 2013

Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

artículo científico

Understanding prognostic gene expression signatures in lung cancer.

scientific article published on September 2009

Ventricular metastasis resulting in disseminated intravascular coagulation

artículo científico publicado en 2005

Vortex Keratopathy Presumed Secondary to AZD9291

artículo científico publicado en 2015

Lista de obras de Thomas John

"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic

A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer

Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer

Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.

Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer

Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing

Current and Evolving Methods to Visualize Biological Data in Cancer Research

DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?

De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer.

Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.

Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.

Do randomized acupuncture studies in patients with cancer need a sham acupuncture control arm?

ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials

Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma

Immunotherapy for malignant mesothelioma: Reality check

Impact of universal immunohistochemistry on Lynch syndrome diagnosis in an Australian colorectal cancer cohort

In Reply to Leone.

Is Mesothelioma in China Rare or Misdiagnosed?

LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

Lung cancer in 2016: immunotherapy comes of age

Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort

Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma

Molecular predictive and prognostic markers in non-small-cell lung cancer.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report

Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

Personalized chemosensitivity assays for mesothelioma- is it worth the effort?

Pharmacogenetic and Germline Prognostic Markers of Lung Cancer

Predicting clinical outcome through molecular profiling in stage III melanoma

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors.

Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).

Should we screen for lung cancer in Australia?

Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease

Standard of care in immunotherapy trials: Challenges and considerations.

Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.

The ADAM Trial: Visiting the Road Less Traveled

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

Understanding prognostic gene expression signatures in lung cancer.

Ventricular metastasis resulting in disseminated intravascular coagulation

Vortex Keratopathy Presumed Secondary to AZD9291